
Stage I

Stage II

MannWhitney U test
p value
(A)R v NR SI; (B) R v NR SI

MannWhitney U test
p value)
(A)SI v SIIR; (B) SI v SII NR



Responders (n = 8)

Nonresponders (n = 7)

Responders (n = 12)

Nonresponders (n = 12)


Difference in Lysholm score

27 (17–38)

− 8 (− 4 to − 17)

34 (17–54)

− 11 (− 4 to − 46)

(A) 0.0003; (B) < 0.0001

(A) 0.21; (B) 0.55

BMI, kg/m^{2}

29 (23–31)

27 (24–31)

27 (23–48)

29 (22–36)

(A) 0.94; (B) 0.54

(A) 0.73; (B) 0.68

Age, years

32 (17–49)

40 (25–50)

40 (17–90)

43 (25–52)

(A) 0.28; (B) 0.92

(A) 0.17; (B) 0.58

Male/female sex, n

8/0

7/0

11/1

10/2

(A) > 0.99; (B) > 0.99

(A) > 0.99; (B) 0.51

Smoker, n

1

2

1

3

(A) 0.54; (B) 0.59

(A) > 0.99; (B) > 0.99

Dilution factor of SF

5 (3–9)

4 (2–7)

4 (1–9)

3 (2–5)

(A) 0.48; (B) 0.25

(A) 0.53; (B) 0.50

Total defect area, cm^{2}

14 (0.4–24)

6 (0.6–12)

6 (1–20)

5 (0.6–12)

(A) 0.74; (B) 0.35

(A) 0.45; (B) 0.28

Patella defect, n

1

1

4

2

(A) > 0.99; (B) 0.64

(A) 0.60; (B) > 0.99

LFC defect, n

2

0

0

0

(A) 0.47; (B) > 0.99

(A) 0.15; (B) > 0.99

LTP defect, n

1

0

0

0

(A) > 0.99; (B) > 0.99

(A) 0.15; (B) > 0.99

MFC defect, n

2

2

1

6

(A) > 0.99; (B) 0.07

(A) 0.54; (B) 0.63

Trochlea defect, n

0

3

2

1

(A) 0.20; (B) > 0.99

(A) 0.49; (B) 0.12

Multiple defects, n

1

0

1

1

(A) > 0.99; (B) > 0.99

(A) > 0.99; (B) > 0.99

Unknown defect location, n

1

1

4

2

(A) > 0.99; (B) 0.64

(A) 0.60; (B) > 0.99

 Footnote: None of the demographic parameters, other than a difference in Lysholm score, showed differences between responders (R) and nonresponders (NR) among individuals whose SF from stage I (SI) or stage II (SII) was compared, nor were there differences between individuals who were either responders or nonresponders when we compared stage I and stage II samples (p ≥ 0.05 by MannWhitney U test). Data are median (range). Abbreviations: BMI Body mass index, LFC Lateral femoral condyle, LTP Lateral tibial plateau, MFC Medial femoral condyle